This website is for UK Healthcare Professionals only

FRONTIERS promotional meetings are fully funded and organised by AbbVie for UK healthcare professionals.

On demand: Access content from previous meetings

18th March 2022

Frontiers: Treating AML in 2022 was a one-day, CPD-accredited meeting for UK HCPs involved in the management of patients with AML. Live presentations and an expert faculty of speakers explored the role of VENCLYXO in AML. We invite you to view key presentations from FRONTIERS 2022.

Professor Andrew Wei

The AML treatment landscape

Discussion on the AML treatment landscape and the arrival of Ven + AZA.

Dr Dominic Culligan, Dr Priyanka Mehta and Dr Richard Dillon

Navigating the therapeutic pathway in patients with newly diagnosed AML

Insights on patient diagnosis and identifying the appropriate treatment for each patient.

Dr Vidhya Murthy, Sumi Gabriel and Katie Higgins

Optimising the treatment journey with Ven + AZA in patients with newly diagnosed AML

A multi-disciplinary panel discuss the key role of the MDT in achieving the best possible outcomes for patients with AML.

Dr Caroline Alvares, Dr Paul Cahalin and Dr Harpreet Kaur

The way forward: models of care

Presenters share models of care and best practice

Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy1

References

  1. VENCLYXTO Summary of Product Characteristics.

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCAML-220173. Date of preparation: July 2022.